{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:28:08Z","timestamp":1789014488113,"version":"build-2803163510"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T00:00:00Z","timestamp":1733097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T00:00:00Z","timestamp":1733097600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Neurol Belg"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s13760-024-02693-9","type":"journal-article","created":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T05:15:07Z","timestamp":1733116507000},"page":"351-358","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Ocular Myasthenia gravis: determining the predictive factors of secondary generalisation"],"prefix":"10.1007","volume":"125","author":[{"given":"Prasana Nair","family":"Gengadharan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei Ting","family":"Ong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie Ying","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nortina","family":"Shahrizaila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khean Jin","family":"Goh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng Yin","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,2]]},"reference":[{"issue":"5","key":"2693_CR1","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1002\/ana.410140504","volume":"14","author":"CT Bever Jr","year":"1983","unstructured":"Bever CT Jr., Aquino AV, Penn AS, Lovelace RE, Rowland LP (1983) Prognosis of ocular myasthenia. Ann Neurol 14(5):516\u2013519. https:\/\/doi.org\/10.1002\/ana.410140504","journal-title":"Ann Neurol"},{"issue":"2","key":"2693_CR2","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1001\/archneur.60.2.243","volume":"60","author":"MJ Kupersmith","year":"2003","unstructured":"Kupersmith MJ, Latkany R, Homel P (2003) Development of generalized disease at 2 years in patients with ocular myasthenia gravis. Arch Neurol 60(2):243\u2013248. https:\/\/doi.org\/10.1001\/archneur.60.2.243","journal-title":"Arch Neurol"},{"issue":"4","key":"2693_CR3","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1111\/ene.12057","volume":"20","author":"H Zach","year":"2013","unstructured":"Zach H, Cetin H, Hilger E, Paul A, Wuschitz B, Jung R, Auff E, Zimprich F (2013) The effect of early prednisolone treatment on the generalization rate in ocular myasthenia gravis. Eur J Neurol 20(4):708\u2013713. https:\/\/doi.org\/10.1111\/ene.12057","journal-title":"Eur J Neurol"},{"issue":"2","key":"2693_CR4","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1002\/mus.20950","volume":"37","author":"D Grob","year":"2008","unstructured":"Grob D, Brunner N, Namba T, Pagala M (2008) Lifetime course of myasthenia gravis. Muscle Nerve 37(2):141\u2013149. https:\/\/doi.org\/10.1002\/mus.20950","journal-title":"Muscle Nerve"},{"issue":"1","key":"2693_CR5","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/1471-2377-10-46","volume":"10","author":"AS Carr","year":"2010","unstructured":"Carr AS, Cardwell CR, McCarron PO, McConville J (2010) A systematic review of population based epidemiological studies in Myasthenia Gravis. BMC Neurol 10(1):46. https:\/\/doi.org\/10.1186\/1471-2377-10-46","journal-title":"BMC Neurol"},{"issue":"1","key":"2693_CR6","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1186\/s12883-020-01805-1","volume":"20","author":"J Ding","year":"2020","unstructured":"Ding J, Zhao S, Ren K, Dang D, Li H, Wu F, Zhang M, Li Z, Guo J (2020) Prediction of generalization of ocular myasthenia gravis under immunosuppressive therapy in Northwest China. BMC Neurol 20(1):238. https:\/\/doi.org\/10.1186\/s12883-020-01805-1","journal-title":"BMC Neurol"},{"issue":"3","key":"2693_CR7","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s13760-018-0943-7","volume":"118","author":"G Galassi","year":"2018","unstructured":"Galassi G, Mazzoli M, Ariatti A, Kaleci S, Valzania F, Nichelli PF (2018) Antibody profile may predict outcome in ocular myasthenia gravis. Acta Neurol Belgica 118(3):435\u2013443. https:\/\/doi.org\/10.1007\/s13760-018-0943-7","journal-title":"Acta Neurol Belgica"},{"issue":"1","key":"2693_CR8","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/mus.22006","volume":"44","author":"JT Guptill","year":"2011","unstructured":"Guptill JT, Sanders DB, Evoli A (2011) Anti-MuSK antibody myasthenia gravis: clinical findings and response to treatment in two large cohorts. Muscle Nerve 44(1):36\u201340. https:\/\/doi.org\/10.1002\/mus.22006","journal-title":"Muscle Nerve"},{"issue":"1","key":"2693_CR9","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.jns.2008.05.023","volume":"273","author":"Y-H Hong","year":"2008","unstructured":"Hong Y-H, Kwon S-B, Kim B-J, Kim BJ, Kim SH, Kim JK, Park K-S, Park K-J, Sung J-J, Sohn EH, Lee Y-B, Jeong D, Joo IS, Choi B-O, Choi Y-C (2008) Prognosis of ocular myasthenia in Korea: a retrospective multicenter analysis of 202 patients. J Neurol Sci 273(1):10\u201314. https:\/\/doi.org\/10.1016\/j.jns.2008.05.023","journal-title":"J Neurol Sci"},{"issue":"12","key":"2693_CR10","doi-asserted-by":"publisher","first-page":"2773","DOI":"10.1007\/s00415-018-9056-8","volume":"265","author":"F Li","year":"2018","unstructured":"Li F, Hotter B, Swierzy M, Ismail M, Meisel A, R\u00fcckert JC (2018) Generalization after ocular onset in myasthenia gravis: a case series in Germany. J Neurol 265(12):2773\u20132782. https:\/\/doi.org\/10.1007\/s00415-018-9056-8","journal-title":"J Neurol"},{"issue":"2","key":"2693_CR11","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.jns.2003.08.017","volume":"217","author":"NT Monsul","year":"2004","unstructured":"Monsul NT, Patwa HS, Knorr AM, Lesser RL, Goldstein JM (2004) The effect of prednisone on the progression from ocular to generalized myasthenia gravis. J Neurol Sci 217(2):131\u2013133. https:\/\/doi.org\/10.1016\/j.jns.2003.08.017","journal-title":"J Neurol Sci"},{"issue":"2","key":"2693_CR12","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1136\/jnnp.62.2.156","volume":"62","author":"N Sommer","year":"1997","unstructured":"Sommer N, Sigg B, Melms A, Weller M, Schepelmann K, Herzau V, Dichgans J (1997) Ocular myasthenia gravis: response to long-term immunosuppressive treatment. J Neurol Neurosurg Psychiatry 62(2):156\u2013162. https:\/\/doi.org\/10.1136\/jnnp.62.2.156","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"5","key":"2693_CR13","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1002\/mus.25983","volume":"57","author":"KY Teo","year":"2018","unstructured":"Teo KY, Tow SL, Haaland B, Gosavi TD, Jing-Liang L, Yew Long LO, Milea D (2018) Low conversion rate of ocular to generalized myasthenia gravis in Singapore. Muscle Nerve 57(5):756\u2013760. https:\/\/doi.org\/10.1002\/mus.25983","journal-title":"Muscle Nerve"},{"issue":"3","key":"2693_CR14","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1097\/wno.0000000000000350","volume":"36","author":"SH Wong","year":"2016","unstructured":"Wong SH, Petrie A, Plant GT (2016) Ocular Myasthenia gravis: toward a risk of generalization score and sample size calculation for a Randomized Controlled Trial of Disease Modification. J Neuroophthalmol 36(3):252\u2013258. https:\/\/doi.org\/10.1097\/wno.0000000000000350","journal-title":"J Neuroophthalmol"},{"issue":"1","key":"2693_CR15","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/S0003-4975(00)01595-2","volume":"70","author":"A Jaretzki","year":"2000","unstructured":"Jaretzki A, Barohn III, Ernstoff RJ, Kaminski RM, Keesey HJ, Penn JC, A. S., Sanders DB (2000) Myasthenia gravis: recommendations for clinical research standards\u2009<\u2009sup\u2009>\u20091. Ann Thorac Surg 70(1):327\u2013334. https:\/\/doi.org\/10.1016\/S0003-4975(00)01595-2","journal-title":"Ann Thorac Surg"},{"issue":"3","key":"2693_CR16","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1002\/mus.24750","volume":"53","author":"E St\u00e5lberg","year":"2016","unstructured":"St\u00e5lberg E, Sanders DB, Ali S, Cooray G, Leonardis L, L\u00f6seth S, Machado F, Maldonado A, Martinez-Aparicio C, Sandberg A, Smith B, Widenfalk J, Kouyoumdjian JA (2016) Reference values for jitter recorded by concentric needle electrodes in healthy controls: a multicenter study. Muscle Nerve 53(3):351\u2013362. https:\/\/doi.org\/10.1002\/mus.24750","journal-title":"Muscle Nerve"},{"key":"2693_CR17","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.ajo.2019.09.019","volume":"209","author":"S Apinyawasisuk","year":"2020","unstructured":"Apinyawasisuk S, Chongpison Y, Thitisaksakul C, Jariyakosol S (2020) Factors affecting generalization of ocular myasthenia gravis in patients with positive acetylcholine receptor antibody. Am J Ophthalmol 209:10\u201317. https:\/\/doi.org\/10.1016\/j.ajo.2019.09.019","journal-title":"Am J Ophthalmol"},{"issue":"19","key":"2693_CR18","doi-asserted-by":"publisher","first-page":"e25899","DOI":"10.1097\/MD.0000000000025899","volume":"100","author":"J Witthayaweerasak","year":"2021","unstructured":"Witthayaweerasak J, Rattanalert N, Aui-Aree N (2021) Prognostic factors for conversion to generalization in ocular myasthenia gravis. Med (Baltim) 100(19):e25899. https:\/\/doi.org\/10.1097\/MD.0000000000025899","journal-title":"Med (Baltim)"},{"issue":"4","key":"2693_CR19","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1002\/mus.25971","volume":"57","author":"SK Kamarajah","year":"2018","unstructured":"Kamarajah SK, Sadalage G, Palmer J, Carley H, Maddison P, Sivaguru A (2018) Ocular presentation of myasthenia gravis: a natural history cohort. Muscle Nerve 57(4):622\u2013627. https:\/\/doi.org\/10.1002\/mus.25971","journal-title":"Muscle Nerve"},{"issue":"1","key":"2693_CR20","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1080\/00207454.2017.1344237","volume":"128","author":"M Mazzoli","year":"2018","unstructured":"Mazzoli M, Ariatti A, Valzania F, Kaleci S, Tondelli M, Nichelli PF, Galassi G (2018) Factors affecting outcome in ocular myasthenia gravis. Int J Neurosci 128(1):15\u201324. https:\/\/doi.org\/10.1080\/00207454.2017.1344237","journal-title":"Int J Neurosci"},{"issue":"7","key":"2693_CR21","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1016\/j.ophtha.2015.03.010","volume":"122","author":"L Nagia","year":"2015","unstructured":"Nagia L, Lemos J, Abusamra K, Cornblath WT, Eggenberger ER (2015) Prognosis of Ocular Myasthenia gravis: Retrospective Multicenter Analysis. Ophthalmology 122(7):1517\u20131521. https:\/\/doi.org\/10.1016\/j.ophtha.2015.03.010","journal-title":"Ophthalmology"},{"issue":"3","key":"2693_CR22","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1002\/ana.410210309","volume":"21","author":"K Kida","year":"1987","unstructured":"Kida K, Hayashi M, Yamada I, Matsuda H, Yoshinaga J, Takami S, Yashiki S, Sonoda S (1987) Heterogeneity in myasthenia gravis: HLA phenotypes and autoantibody responses in ocular and generalized types. Ann Neurol 21(3):274\u2013278. https:\/\/doi.org\/10.1002\/ana.410210309","journal-title":"Ann Neurol"},{"issue":"2","key":"2693_CR23","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1172\/jci114724","volume":"86","author":"K Matsuki","year":"1990","unstructured":"Matsuki K, Juji T, Tokunaga K, Takamizawa M, Maeda H, Soda M, Nomura Y, Segawa M (1990) HLA antigens in Japanese patients with myasthenia gravis. J Clin Invest 86(2):392\u2013399. https:\/\/doi.org\/10.1172\/jci114724","journal-title":"J Clin Invest"},{"issue":"5","key":"2693_CR24","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1111\/j.1399-0039.1987.tb01586.x","volume":"29","author":"P Thajeb","year":"1987","unstructured":"Thajeb P, Chee CY, Huang CC (1987) The distribution of HLA-A,B, DR antigens in Chinese myasthenia gravis. Tissue Antigens 29(5):273\u2013279. https:\/\/doi.org\/10.1111\/j.1399-0039.1987.tb01586.x","journal-title":"Tissue Antigens"},{"issue":"3\u20134","key":"2693_CR25","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1159\/000487132","volume":"79","author":"F Aguirre","year":"2018","unstructured":"Aguirre F, Villa AM (2018) Prognosis of Ocular Myasthenia gravis in an Argentinian Population. Eur Neurol 79(3\u20134):113\u2013117. https:\/\/doi.org\/10.1159\/000487132","journal-title":"Eur Neurol"},{"key":"2693_CR26","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.ajo.2019.04.017","volume":"205","author":"TM Hendricks","year":"2019","unstructured":"Hendricks TM, Bhatti MT, Hodge DO, Chen JJ (2019) Incidence, epidemiology, and transformation of ocular myasthenia gravis: a population-based study. Am J Ophthalmol 205:99\u2013105. https:\/\/doi.org\/10.1016\/j.ajo.2019.04.017","journal-title":"Am J Ophthalmol"},{"key":"2693_CR27","doi-asserted-by":"publisher","first-page":"77","DOI":"10.3389\/fneur.2018.00077","volume":"9","author":"X Huang","year":"2018","unstructured":"Huang X, Li Y, Feng H, Chen P, Liu W (2018) Clinical characteristics of Juvenile Myasthenia gravis in Southern China. Front Neurol 9:77\u201377. https:\/\/doi.org\/10.3389\/fneur.2018.00077","journal-title":"Front Neurol"},{"issue":"2","key":"2693_CR28","doi-asserted-by":"publisher","first-page":"265","DOI":"10.3988\/jcn.2021.17.2.265","volume":"17","author":"KH Kim","year":"2021","unstructured":"Kim KH, Kim SW, Shin HY (2021) Initial repetitive nerve stimulation test predicts conversion of ocular myasthenia gravis to generalized myasthenia gravis. J Clin Neurol 17(2):265\u2013272. https:\/\/doi.org\/10.3988\/jcn.2021.17.2.265","journal-title":"J Clin Neurol"},{"issue":"2","key":"2693_CR29","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1159\/000507853","volume":"83","author":"X Feng","year":"2020","unstructured":"Feng X, Huan X, Yan C, Song J, Lu J, Zhou L, Wu H, Qiao K, Lu J, Xi J, Luo S, Zhao C (2020) Adult ocular myasthenia gravis conversion: a single-center retrospective analysis in China. Eur Neurol 83(2):182\u2013188. https:\/\/doi.org\/10.1159\/000507853","journal-title":"Eur Neurol"},{"issue":"4","key":"2693_CR30","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/mus.23944","volume":"49","author":"DB Sanders","year":"2014","unstructured":"Sanders DB, Burns TM, Cutter GR, Massey JM, Juel VC, Hobson-Webb L, Muscle Study Group (2014) Does change in acetylcholine receptor antibody level correlate with clinical change in myasthenia gravis? Muscle Nerve 49(4):483\u2013486. https:\/\/doi.org\/10.1002\/mus.23944","journal-title":"Muscle Nerve"},{"issue":"7","key":"2693_CR31","doi-asserted-by":"publisher","first-page":"e02203","DOI":"10.1002\/brb3.2203","volume":"11","author":"L Wang","year":"2021","unstructured":"Wang L, Wang S, Yang H, Han J, Zhao X, Han S, Zhang Y, Lv J, Zhang J, Li M, Ji Y, Zhou S, He X, Fang H, Yang J, Zhang Y, Zhang Q, Gao P, Gao F (2021) No correlation between acetylcholine receptor antibody concentration and individual clinical symptoms of myasthenia gravis: a systemic retrospective study involving 67 patients. Brain Behav 11(7):e02203. https:\/\/doi.org\/10.1002\/brb3.2203","journal-title":"Brain Behav"},{"issue":"1","key":"2693_CR32","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1111\/ene.15565","volume":"30","author":"A Meisel","year":"2023","unstructured":"Meisel A, Baggi F, Behin A, Evoli A, Kostera-Pruszczyk A, Mantegazza R, Morales RJ, Punga AR, Sacconi S, Schroeter M, Verschuuren J, Crathorne L, Holmes K, Leite MI (2023) Role of autoantibody levels as biomarkers in the management of patients with myasthenia gravis: a systematic review and expert appraisal. Eur J Neurol 30(1):266\u2013282. https:\/\/doi.org\/10.1111\/ene.15565","journal-title":"Eur J Neurol"},{"key":"2693_CR33","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-73585-6_8","volume-title":"Myasthenia Gravis and Related disorders. Current clinical neurology","author":"A Marx","year":"2018","unstructured":"Marx A, Str\u00f6bel P, Weis CA (2018) Thymoma-Associated Myasthenia Gravis. In: Kaminski H, Kusner L (eds) Myasthenia Gravis and Related disorders. Current clinical neurology. Humana, Cham. https:\/\/doi.org\/10.1007\/978-3-319-73585-6_8"},{"issue":"3","key":"2693_CR34","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1002\/mus.21555","volume":"41","author":"JA Allen","year":"2010","unstructured":"Allen JA, Scala S, Jones HR (2010) Ocular myasthenia gravis in a senior population: diagnosis, therapy, and prognosis. Muscle Nerve 41(3):379\u2013384. https:\/\/doi.org\/10.1002\/mus.21555","journal-title":"Muscle Nerve"},{"issue":"4","key":"2693_CR35","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1097\/00041327-200312000-00002","volume":"23","author":"J Mee","year":"2003","unstructured":"Mee J, Paine M, Byrne E, King J, Reardon K, O\u2019Day J (2003) Immunotherapy of ocular myasthenia gravis reduces conversion to generalized myasthenia gravis. J Neuroophthalmol 23(4):251\u2013255. https:\/\/doi.org\/10.1097\/00041327-200312000-00002","journal-title":"J Neuroophthalmol"},{"issue":"8","key":"2693_CR36","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1001\/archneur.1996.00550080128020","volume":"53","author":"MJ Kupersmith","year":"1996","unstructured":"Kupersmith MJ, Moster M, Bhuiyan S, Warren F, Weinberg H (1996) Beneficial effects of corticosteroids on ocular myasthenia gravis. Arch Neurol 53(8):802\u2013804. https:\/\/doi.org\/10.1001\/archneur.1996.00550080128020","journal-title":"Arch Neurol"},{"issue":"1","key":"2693_CR37","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s12883-017-0857-7","volume":"17","author":"L Wang","year":"2017","unstructured":"Wang L, Zhang Y, He M (2017) Clinical predictors for the prognosis of myasthenia gravis. BMC Neurol 17(1):77. https:\/\/doi.org\/10.1186\/s12883-017-0857-7","journal-title":"BMC Neurol"},{"issue":"8","key":"2693_CR38","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1007\/s00415-016-8045-z","volume":"263","author":"N Melzer","year":"2016","unstructured":"Melzer N, Ruck T, Fuhr P, Gold R, Hohlfeld R, Marx A, Melms A, Tackenberg B, Schalke B, Schneider-Gold C, Zimprich F, Meuth SG, Wiendl H (2016) Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the guidelines of the German neurological society. J Neurol 263(8):1473\u20131494. https:\/\/doi.org\/10.1007\/s00415-016-8045-z","journal-title":"J Neurol"}],"container-title":["Acta Neurologica Belgica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13760-024-02693-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13760-024-02693-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13760-024-02693-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T04:51:05Z","timestamp":1745297465000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13760-024-02693-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,2]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["2693"],"URL":"https:\/\/doi.org\/10.1007\/s13760-024-02693-9","relation":{},"ISSN":["0300-9009","2240-2993"],"issn-type":[{"value":"0300-9009","type":"print"},{"value":"2240-2993","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,2]]},"assertion":[{"value":"22 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Medical Research Ethics Committee of University Malaya Medical Centre (202185\u2009\u2212\u200910461).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was waived by the ethics committee in view of the retrospective nature of the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}